Bioventus (NASDAQ:BVS) Shares Gap Down Following Analyst Downgrade

Key Points

• Bioventus shares fell 15.8%, opening at $11.02 after Canaccord Genuity cut its price target from $19 to $18, although it maintained a buy rating.
• Third-quarter adjusted EPS of $0.17 matched expectations and rose from $0.15 a year earlier, while management reaffirmed its 2026 adjusted EPS outlook of $0.75–$0.79.
• The company lowered its 2026 revenue guidance to $590–$595 million, below the $604.6 million consensus estimate, raising concerns about slowing growth and whether profit gains are being driven mainly by debt reduction rather than operations.

Bioventus Inc. (NASDAQ:BVS - Get Free Report)'s share price gapped down prior to trading on Tuesday after Canaccord Genuity Group lowered their price target on the stock from $19.00 to $18.00. The stock had previously closed at $13.15, but opened at $11.02. Canaccord Genuity Group currently has a buy rating on the stock. Bioventus shares last traded at $11.1550, with a volume of 392,065 shares trading hands.

A number of other equities analysts have also recently issued reports on BVS. Weiss Ratings upgraded Bioventus from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. Craig Hallum reaffirmed a "buy" rating and set a $18.00 target price on shares of Bioventus in a report on Thursday, August 6th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday, August 17th. Finally, Barrington Research set a $18.00 price target on Bioventus in a research note on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $16.60.

Bioventus News Summary

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching analyst expectations and increasing from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS beat or in-line result. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its fiscal 2026 adjusted EPS outlook of $0.75 to $0.79, broadly consistent with the $0.78 consensus estimate. The company’s earnings performance also benefited from debt paydown and lower interest costs. Bioventus Fiscal 2026 Outlook
• Neutral Sentiment: Third-quarter revenue was $142.44 million, while return on equity was 28.08% and net margin was 9.36%. Investors are assessing whether improving profitability can offset slower top-line growth. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut fiscal 2026 revenue guidance to $590 million-$595 million from a level implied by the prior outlook, below the $604.6 million consensus estimate. The reduction signals weaker operational growth and was the main source of investor pressure. Bioventus Sales Miss and Outlook Cut
• Negative Sentiment: Commentary characterized earnings growth as being driven more by debt reduction than by underlying operations, raising concerns about the sustainability of profit improvement if revenue momentum remains limited. Bioventus Earnings Growth and Revenue Outlook

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Covestor Ltd raised its position in Bioventus by 25.6% during the third quarter. Covestor Ltd now owns 5,808 shares of the company's stock valued at $79,000 after buying an additional 1,182 shares during the period. Signaturefd LLC lifted its stake in Bioventus by 2,809.1% in the 3rd quarter. Signaturefd LLC now owns 1,920 shares of the company's stock worth $26,000 after acquiring an additional 1,854 shares in the last quarter. Quantum Financial Partners LLC boosted its position in Bioventus by 11.8% during the 3rd quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company's stock worth $194,000 after acquiring an additional 1,500 shares during the period. USA Financial Formulas acquired a new stake in Bioventus during the 3rd quarter worth about $42,000. Finally, State of Alaska Department of Revenue grew its stake in Bioventus by 446.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 18,953 shares of the company's stock valued at $258,000 after acquiring an additional 15,484 shares in the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Trading Down 15.8%

The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. The company has a 50 day simple moving average of $13.68 and a two-hundred day simple moving average of $10.90. The company has a market cap of $930.54 million, a PE ratio of 14.48, a PEG ratio of 1.87 and a beta of 0.64.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.17. The business had revenue of $142.44 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Sell-side analysts forecast that Bioventus Inc. will post 0.79 EPS for the current year.

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company's offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.